KR101902932B1 - A composition for preventing, improving or treating alcoholic gastritis of the extracts from the aerial parts except flower and root of Cirsium japonicum and Taraxacum coreanum - Google Patents
A composition for preventing, improving or treating alcoholic gastritis of the extracts from the aerial parts except flower and root of Cirsium japonicum and Taraxacum coreanum Download PDFInfo
- Publication number
- KR101902932B1 KR101902932B1 KR1020160179611A KR20160179611A KR101902932B1 KR 101902932 B1 KR101902932 B1 KR 101902932B1 KR 1020160179611 A KR1020160179611 A KR 1020160179611A KR 20160179611 A KR20160179611 A KR 20160179611A KR 101902932 B1 KR101902932 B1 KR 101902932B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- thistle
- mixture
- white dandelion
- preventing
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 110
- 239000000203 mixture Substances 0.000 title claims abstract description 104
- 206010017856 Gastritis alcoholic Diseases 0.000 title claims abstract description 23
- 201000005988 alcoholic gastritis Diseases 0.000 title claims abstract description 23
- 241001272081 Taraxacum coreanum Species 0.000 title claims description 10
- 241000729173 Cirsium japonicum Species 0.000 title claims description 8
- 241000132536 Cirsium Species 0.000 claims abstract description 85
- 241000245665 Taraxacum Species 0.000 claims abstract description 79
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 76
- 230000036541 health Effects 0.000 claims abstract description 25
- 210000002784 stomach Anatomy 0.000 claims abstract description 23
- 239000004480 active ingredient Substances 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 235000013376 functional food Nutrition 0.000 claims abstract description 16
- 206010061218 Inflammation Diseases 0.000 claims abstract description 11
- 230000004054 inflammatory process Effects 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 86
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 9
- 239000012046 mixed solvent Substances 0.000 claims description 4
- 229940067866 dandelion extract Drugs 0.000 claims description 2
- 235000020691 dandelion extract Nutrition 0.000 claims description 2
- 239000001845 taraxacum officinale leaf extract Substances 0.000 claims description 2
- 239000000419 plant extract Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 32
- 210000001519 tissue Anatomy 0.000 abstract description 22
- 208000022309 Alcoholic Liver disease Diseases 0.000 abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 201000010099 disease Diseases 0.000 abstract description 11
- 210000005228 liver tissue Anatomy 0.000 abstract description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 4
- 239000001301 oxygen Substances 0.000 abstract description 4
- 229910052760 oxygen Inorganic materials 0.000 abstract description 4
- 238000011282 treatment Methods 0.000 description 26
- 239000003814 drug Substances 0.000 description 18
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 16
- 108010082126 Alanine transaminase Proteins 0.000 description 16
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 15
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 13
- 238000002156 mixing Methods 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 208000007882 Gastritis Diseases 0.000 description 10
- 230000036542 oxidative stress Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000003085 diluting agent Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 230000006378 damage Effects 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 7
- 206010028851 Necrosis Diseases 0.000 description 6
- 208000007107 Stomach Ulcer Diseases 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000017074 necrotic cell death Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 206010067125 Liver injury Diseases 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 201000005917 gastric ulcer Diseases 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 235000015278 beef Nutrition 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 240000003768 Solanum lycopersicum Species 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- -1 dimethyl dimethoxybiphenylate Chemical compound 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 235000008960 ketchup Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 235000015067 sauces Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000208838 Asteraceae Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241001107116 Castanospermum australe Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009858 acid secretion Effects 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000021279 black bean Nutrition 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 235000014171 carbonated beverage Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940069445 licorice extract Drugs 0.000 description 2
- 238000012317 liver biopsy Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 229930193195 schizandrin Natural products 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 244000044283 Toxicodendron succedaneum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 1
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000004464 cereal grain Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003028 enzyme activity measurement method Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 엉겅퀴와 흰민들레 전초 추출물의 혼합물을 유효성분으로 함유하는 알코올성 간 손상 또는 알코올성 위염의 예방, 개선 또는 치료용 조성물에 관한 것으로, 더욱 상세하게는 GOT 및 GPT의 활성을 저해하거나 또는 증가된 간 조직의 무게를 감소시키는 효과 및/또는 위 조직에서 활성산소종을 감소시키거나 위 조직의 염증을 완화시키는 효과를 나타내는 엉겅퀴와 흰민들레 전초 추출물의 혼합물을 이용하여 알코올성 간 손상 및/또는 알코올성 위염의 예방, 개선 또는 치료용 약학적 조성물 및 건강기능식품을 제공한다.The present invention relates to a composition for preventing, ameliorating or treating alcoholic liver damage or alcoholic gastritis containing, as an active ingredient, a mixture of thistle and white dandelion outpost extract, and more particularly to a composition for preventing, improving or treating GOT and GPT activity, A mixture of thistle and white dandelion outpost extract, which has the effect of reducing the weight of the liver tissue and / or reducing the active oxygen species in the stomach tissue or alleviating the inflammation of the stomach tissue, is used to treat alcoholic liver damage and / or alcoholic gastritis A pharmaceutical composition for preventing, ameliorating or treating the aforementioned diseases, and a health functional food.
Description
본 발명은 엉겅퀴 및 흰민들레 전초 추출물을 유효성분으로 함유하는 알코올성 간 손상 또는 알코올성 위염의 예방, 개선 또는 치료용 조성물에 관한 것으로, 더욱 상세하게는 GOT 및 GPT의 활성을 저해하거나 또는 증가된 간 조직의 무게를 감소시키는 효과 및/또는 위 조직에서 활성산소종을 감소시키거나 위 조직의 염증을 완화시키는 효과를 나타내는 엉겅퀴와 흰민들레 전초 추출물의 혼합물을 이용하여 알코올성 간 손상 및/또는 알코올성 위염의 예방, 개선 또는 치료용 약학적 조성물 및 건강기능식품을 제공한다.The present invention relates to a composition for preventing, ameliorating or treating alcoholic liver damage or alcoholic gastritis containing thistle and white dandelion outbreak extract as an active ingredient, and more particularly to a composition for preventing, improving or treating GOT and GPT, And / or prevention of alcoholic liver damage and / or alcoholic gastritis by using a mixture of thistle and white dandelion outpost extract which has the effect of reducing the weight of the stomach and / or reducing the active oxygen species in the stomach tissue or alleviating the inflammation of the stomach tissue , A pharmaceutical composition for improvement or treatment, and a health functional food.
우리나라의 경우 20세 이상 성인 남자의 음주율은 83.3%로 매우 높고 여성의 음주율 또한 54.9%로 급격히 증가하는 추세에 있으며, 잘못된 음주문화로 인하여 과음에 심각하게 노출되어 있다. 알코올의 과다 섭취로 인한 폐해는 간질환을 비롯하여 각종 질환의 병인이 됨은 물론 개인, 가정, 사회의 정서와 생활에 부정적인 영향을 미침으로써 국가적으로 막대한 경제, 사회적 손실을 야기하고 있다.In Korea, the drinking rate of men over 20 years old is very high (83.3%), and the rate of women drinking is also rapidly increasing to 54.9%, which is seriously exposed to excessive drinking due to wrong drinking culture. The harmful effects caused by excessive consumption of alcohol are not only a pathogen of various diseases such as liver disease but also have a negative effect on the emotion and life of the individual, family and society, resulting in enormous national and economic losses.
급성 알코올 섭취는 사람들에게 있어 직접적으로 또는 간접적으로 독성작용을 일으키는 것으로 알려져 있으며, 아세트알데하이드와 아세테이트와 같은 생성물은 간세포에 손상을 야기한다. 섭취한 에탄올의 80-90% 이상이 간에서 대사되며 에탄올은 아세트알데하이드로 산화된다. 간에서의 에탄올 독성은 에탄올 대사에 의해 야기되는 산화적 스트레스로 설명된다. 에탄올 또는 이의 대사산물은 간세포에서 자동산화를 일으키며 산화촉진성(pro-oxidative) 인자로서의 작용 또는 항산화 수준을 감소시킴으로써 간염을 일으킨다. 또한 지질산화와 막 손상과의 관련은 에탄올성 간 손상에서 중요한 특징이다.Acute alcohol consumption is known to cause direct or indirect toxic effects in people, and products such as acetaldehyde and acetate cause damage to the hepatocytes. More than 80-90% of the ethanol ingested is metabolized in the liver and ethanol is oxidized to acetaldehyde. Ethanol toxicity in the liver is explained by oxidative stress caused by ethanol metabolism. Ethanol or its metabolites cause autoxidation in hepatocytes and produce hepatitis by acting as a pro-oxidative factor or reducing antioxidant levels. The association of lipid oxidation with membrane damage is also an important feature of ethanolic liver damage.
따라서, 이들의 초기반응을 저해할 수 있는 간 보호활성물질이나 간염 치료제의 개발이 요구되고 있다. 최근 개발된 디메닐 디메톡시 비페닐레이트(dimethyl dimethoxybiphenylate)는 오미자의 성분인 쉬잔드린(schizandrin)과 유사한 합성물질로 간독성 치료 효과가 보고된 바 있으나, 이들 질환의 심각성과 빈도수를 고려해 효과적으로 작용하기 위한 천연물에서의 간질환 예방 또는 치료제의 개발이 절실히 필요한 실정이다. Accordingly, development of a hepatoprotective agent and a hepatitis therapeutic agent capable of inhibiting the initial reaction thereof is required. Recently, dimethyl dimethoxybiphenylate has been reported to be a synthetic substance similar to schizandrin, a component of Schizandrin, and has been reported to be effective against hepatotoxicity in consideration of the severity and frequency of these diseases The development of a preventive or therapeutic agent for liver diseases in natural products is urgently needed.
또한, 알코올성 위염은 알코올로 인한 만성적인 자극에 의해 위 점막이 손상된 상태를 일컫는다. 알코올성 위염에 걸리면 소화가 잘 되지 않고 쓰린 느낌을 호소하는 경우도 있지만 대부분 특별한 증상이 없다가 내시경 검사와 초음파 검사를 통해 심각한 증상이 발견된다. 만성적으로 술을 마시는 경우 위염뿐만 아니라 췌장이나 간 등도 손상시켜 관련질환을 유발하며, 또한 식도암, 위암, 대장암의 위험도 높아진다.In addition, alcoholic gastritis refers to a condition in which the gastric mucosa is damaged by chronic stimuli due to alcohol. Alcoholic gastritis is not easy to digest and sometimes feel sore, but most of the symptoms are not specific symptoms through endoscopy and ultrasonography is found. Chronic drinking does not only lead to gastritis, but also damage the pancreas and liver, leading to related diseases, and also increases the risk of esophageal cancer, stomach cancer and colon cancer.
특히, 알코올로 인한 위염 및 위궤양은 가장 주의를 요하는데, 알코올은 위벽의 세포를 자극해 산 분비를 증가시키며, 과도한 알코올 섭취는 위점막의 부종을 발생시켜 출혈을 일으키고 염증세포들의 생성을 유도한다. 또한, 산화적 스트레스로 인한 괴사 혹은 세포사멸을 유도하여 위점막을 손상시키고, 위출혈이 나타나게 된다.In particular, gastritis and gastric ulceration due to alcohol require the most attention. Alcohol stimulates the cells of the gastric wall to increase acid secretion. Excessive alcohol consumption causes edema of the gastric mucosa, leading to bleeding and induction of inflammatory cells . In addition, it induces necrosis or cell death due to oxidative stress, damaging the gastric mucosa and causing gastrointestinal bleeding.
종래의 위염 및 위궤양의 치료제로는 과다 분비된 위산을 중화시키는 제산제(antacid), 산 분비 억제 목적의 히스타민 길항제(histamine antagonist), 프로톤 펌프 저해제(proton pump inhibitor), 콜린 억제제, 위내막의 내성을 증가시키고 회복을 돕는 위점막보호제 등이 있다. 다만, 이와 같은 치료제들은 합성 의약품으로 식욕감퇴, 무력감, 알레르기 등의 부작용이 발생하는 문제점이 있었다.Conventional treatments for gastritis and gastric ulcers include antacids that neutralize excess secreted acid, histamine antagonists to inhibit acid secretion, proton pump inhibitors, cholinergic inhibitors, and resistance to gastric lining And gastric mucosal protective agents that help increase recovery. However, such therapeutic agents are synthetic drugs and have side effects such as loss of appetite, weakness, and allergy.
이에, 대한민국 공개특허 제10-2009-0046425호(천마 추출물을 함유하는 위염 또는 위궤양의 예방 또는 치료용 조성물), 대한민국 등록특허 제10-1091025호(복분자 추출물을 함유하는 비스테로이드성 항염증제에 의해 유발된 위염 및 위궤양 예방 및 치료용 조성물), 대한민국 공개특허 제10-2012-0051904호(옻나무 추출물을 포함하는 위염 및 위궤양 치료제 조성물), 대한민국 등록특허 제10-1204981호(고로쇠 수액을 함유하는 위염 및 위궤양의 예방 및 치료용 조성물) 등 위염 및 위궤양의 예방 및 치료 효과가 있는 천연 추출물에 대한 관심이 높아지고 있다. Accordingly, Korean Patent Publication No. 10-2009-0046425 (composition for preventing or treating gastritis or gastric ulcer containing Ganoderma extract), Korean Patent No. 10-1091025 (induced by non-steroidal anti-inflammatory drug containing bokbunja extract Korean Patent Laid-Open Publication No. 10-2012-0051904 (composition for treating gastritis and gastric ulcer including Rhus verniciflua extract), Korean Patent No. 10-1204981 (composition for prevention and treatment of gastritis and gastric ulcer comprising Gonorrhea sap) There is a growing interest in natural extracts having preventive and therapeutic effects of gastritis and gastric ulcer.
이러한 배경 하에, 본 발명자들은 엉겅퀴와 흰민들레 전초 추출물의 혼합물이 알코올성 간 손상과 알코올성 위염을 개선시키는 효과가 있음을 확인하고 본 발명을 완성하였다.Under these circumstances, the present inventors have confirmed that a mixture of thistle and white dandelion outpost extract has the effect of improving alcoholic liver damage and alcoholic gastritis, and completed the present invention.
본 발명은 상기와 같은 문제점을 해결하기 위해 안출된 것으로, 엉겅퀴와 흰민들레 전초 추출물의 혼합물을 유효성분으로 함유하는 알코올성 간 손상의 예방, 개선 또는 치료용 조성물을 제공하는데 목적이 있다.SUMMARY OF THE INVENTION The present invention has been made to solve the above-mentioned problems, and it is an object of the present invention to provide a composition for preventing, improving or treating alcoholic liver damage containing a mixture of thistle and white dandelion seedling extract as an active ingredient.
본 발명의 다른 목적은 엉겅퀴와 흰민들레 전초 추출물의 혼합물을 유효성분으로 함유하는 알코올성 위염의 예방, 개선 또는 치료용 조성물을 제공하는데 목적이 있다.It is another object of the present invention to provide a composition for preventing, improving or treating alcoholic gastritis containing a mixture of thistle and white dandelion seed extract as an active ingredient.
상술한 과제를 해결하기 위해, 본 발명은 엉겅퀴(Cirsium japonicum) 및 흰민들레(Taraxacum coreanum) 전초 추출물의 혼합물을 유효성분으로 함유하는 알코올성 간 손상의 예방 또는 치료용 약학적 조성물을 제공한다.In order to solve the above problems, the present invention thistle (Cirsium The present invention also provides a pharmaceutical composition for preventing or treating alcoholic liver damage containing a mixture of an extract of Taraxacum coreanum and an extract of Taraxacum coreanum as an active ingredient.
본 발명은 또한, 엉겅퀴 추출물(Cirsium japonicum)와 흰민들레(Taraxacum coreanum) 전초 추출물의 혼합물을 유효성분으로 함유하는 알코올성 간 손상의 예방 또는 개선용 건강기능식품 조성물을 제공한다.The present invention also provides a health functional food composition for preventing or ameliorating alcoholic liver damage containing a mixture of Cirsium japonicum and Taraxacum coreanum outpost extract as an active ingredient.
본 발명의 바람직한 일실시예에 따르면, 상기 엉겅퀴와 흰민들레 엉겅퀴와 흰민들레 전초 추출물은 물, C1 ~ C4의 알코올 또는 이들의 혼합용매로 추출할 수 있다.According to a preferred embodiment of the present invention, the thistle, the white dandelion thistle and the white dandelion outpost extract can be extracted with water, a C 1 to C 4 alcohol, or a mixed solvent thereof.
본 발명의 바람직한 다른 일실시예에 따르면, 상기 엉겅퀴와 흰민들레 전초 추출물은 1:0.25 내지 1:1의 중량비로 함유될 수 있다.According to another preferred embodiment of the present invention, the thistle and the white dandelion outpost extract may be contained in a weight ratio of 1: 0.25 to 1: 1.
본 발명의 바람직한 또 다른 일실시예에 따르면, 상기 조성물은 GOT 및 GPT의 활성을 저해하거나 또는 증가된 간 조직의 무게를 감소시킬 수 있다.According to another preferred embodiment of the present invention, the composition may inhibit the activity of GOT and GPT or may reduce the weight of the increased liver tissue.
나아가, 본 발명은 엉겅퀴(Cirsium japonicum) 및 흰민들레(Taraxacum coreanum) 전초 추출물의 혼합물을 유효성분으로 함유하는 알코올성 위염의 예방 또는 치료용 약학적 조성물을 제공한다.Furthermore, the present invention thistle (Cirsium japonicum ) and white dandelion ( Taraxacum The present invention provides a pharmaceutical composition for preventing or treating alcoholic gastritis containing as an active ingredient a mixture of a coreanum extract.
본 발명은 또한, 엉겅퀴(Cirsium japonicum) 및 흰민들레(Taraxacum coreanum) 전초 추출물의 혼합물을 유효성분으로 함유하는 알코올성 위염의 예방 또는 개선용 건강기능식품 조성물을 제공한다.The present invention also relates to a method for the treatment of cirsium The present invention provides a health functional food composition for preventing or alleviating an alcoholic gastritis containing, as an active ingredient, a mixture of an extract of Taraxacum coreanum and an extract of a white dandelion ( Taraxacum coreanum ).
본 발명의 바람직한 일실시예에 따르면, 상기 엉겅퀴와 흰민들레 전초 추출물은 물, C1 ~ C4의 알코올 또는 이들의 혼합용매로 추출할 수 있다.According to a preferred embodiment of the present invention, the thistle and the white dandelion seedling extract can be extracted with water, a C 1 to C 4 alcohol, or a mixed solvent thereof.
본 발명의 바람직한 다른 일실시예에 따르면, 상기 엉겅퀴와 흰민들레 전초 추출물은 1:0.25 내지 1:4의 중량비로 함유될 수 있다.According to another preferred embodiment of the present invention, the thistle and the white dandelion outpost extract may be contained in a weight ratio of 1: 0.25 to 1: 4.
본 발명의 바람직한 또 다른 일실시예에 따르면, 상기 조성물은 위 조직에서 활성산소종(reactive oxygen species)을 감소시키거나 위 조직의 염증을 완화시킬 수 있다.According to another preferred embodiment of the present invention, the composition may reduce reactive oxygen species in the stomach tissue or alleviate inflammation of the stomach tissue.
본 발명에 따른 엉겅퀴와 흰민들레 전초 추출물의 혼합물을 유효성분으로 함유하는 조성물은 알코올에 의해 손상된 간 조직에서 GOT 및 GPT의 활성을 저해하는 효과가 매우 우수하고, 증가된 간 무게의 감소 및 간세포의 괴사와 변성을 감소시켜 알코올성 간 손상을 예방, 개선 또는 치료하는데 유용하다. 또한, 본 발명의 조성물은 알코올로 유발된 위 조직의 산화 스트레스 감소 및 염증 완화 효과가 뛰어나 알코올성 위염을 예방, 개선 또는 치료하는데 유용하다.The composition containing the mixture of thistle and white dandelion seed extract according to the present invention as an active ingredient has excellent effect of inhibiting the activity of GOT and GPT in liver damaged by alcohol, It is useful for preventing, ameliorating or treating alcoholic liver damage by reducing necrosis and degeneration. In addition, the composition of the present invention is useful for preventing, ameliorating or treating alcoholic gastritis by excelling in the reduction of oxidative stress and inflammation of the stomach tissue induced by alcohol.
나아가, 본 발명의 조성물은 천연물 소재의 추출물을 유효성분으로 하여 인체에 안전하고, 부작용이 적어 의약품, 의약외품 및 건강기능식품등의 개발에 소재로 적합하다.Furthermore, the composition of the present invention is safe as a human body and has few side effects, and is suitable as a material for the development of medicines, quasi-drugs and health functional foods.
도 1은 알코올 투여로 간 손상을 일으킨 쥐에서 엉겅퀴와 흰민들레 전초 추출물의 다양한 중량비로 혼합된 혼합물 처리에 따른 GOP 수치(A) 및 GPT 수치(B) 저해 효과를 나타낸 그래프이다.
도 2는 알코올로 투여로 간 무게가 증가된 쥐에서 엉겅퀴와 흰민들레 전초 추출물의 다양한 중량비로 혼합된 혼합물 처리에 따른 간 무게 감소 효과를 나타낸 그래프이다.
도 3은 알코올 투여로 간 손상을 일으킨 쥐에서 엉겅퀴와 흰민들레 전초 추출물의 다양한 중량비로 혼합된 혼합물 처리에 따른 간 조직의 미세구조 변화를 보여주는 사진이다.
도 4는 알코올 투여로 산화적 스트레스가 증가된 쥐의 위 조직에서 엉겅퀴와 흰민들레 전초 추출물의 다양한 중량비로 혼합된 혼합물 처리에 따른 활성산소종(ROS)의 감소 효과를 나타낸 그래프이다.
도 5는 알코올 투여로 위염이 유발된 쥐의 위 조직에서 엉겅퀴와 흰민들레 전초 추출물의 다양한 중량비로 혼합된 혼합물 처리에 따른 염증 완화 정도를 보여주는 사진이다.FIG. 1 is a graph showing the inhibitory effects of GOP values (A) and GPT values (B) upon treatment of mixed mixtures at various weight ratios of thistle and white dandelion outpost extract in liver damaged by alcohol administration.
FIG. 2 is a graph showing the effect of liver weight reduction according to various mixture treatments at various weight ratios of thistle and white dandelion outpost extract in rats in which liver weight was increased by alcohol administration.
FIG. 3 is a photograph showing changes in the microstructure of liver tissues according to various mixture treatments at various weight ratios of thistle and white dandelion outpost extract in rats caused by alcohol administration by alcohol administration.
FIG. 4 is a graph showing a reduction effect of reactive oxygen species (ROS) according to various mixture treatments at various weight ratios of thistle and white dandelion outpost extract in rat stomach tissues in which oxidative stress was increased by alcohol administration.
FIG. 5 is a photograph showing the degree of inflammation relief according to the treatment of the mixture mixed at various weight ratios of thistle and white dandelion outpost extract in the stomach tissue of gastritis induced by alcohol administration.
이하, 본 발명을 더욱 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
상술한 바와 같이, 알코올로 인한 간 손상으로 유발되는 간 질환은 그 심각성과 빈도수를 고려해 효과적으로 작용하는 천연물 소재의 치료제 개발이 요구되고 있다. 또한, 종래의 위염 또는 위궤양 치료제의 부작용은 천연물 소재의 알코올성 위염 치료제 개발 및 치료방법에 대한 요구를 증가시키고 있다.As described above, it is required to develop a therapeutic agent for a natural material which effectively acts on liver disease caused by liver damage due to alcohol, taking into consideration the severity and the frequency. In addition, the conventional side effects of the gastritis or gastric ulcer therapeutic agent are increasingly demanded for the development and treatment of alcoholic gastritis treatment of natural materials.
이에, 본 발명은 엉겅퀴와 흰민들레 전초 추출물의 혼합물을 유효성분으로 함유하는 조성물을 제공함으로써 상술한 문제의 해결방안을 모색하였다. 본 발명에 따른 엉겅퀴와 흰민들레 전초 추출물의 혼합물을 유효성분으로 함유하는 약학적 조성물 및 건강기능식품 조성물은 GOT 및 GPT의 활성을 저해하는 효과가 매우 우수하고, 증가된 간 무게의 감소 및 간세포의 괴사와 변성을 감소시켜 알코올성 간 손상을 예방, 개선 또는 치료하는데 유용하고, 또한, 알코올로 유발된 위 조직의 산화 스트레스 감소 및 염증 완화 효과가 뛰어나 알코올성 위염을 예방, 개선 또는 치료하는데 유용하다.Accordingly, the present invention has solved the above-mentioned problem by providing a composition containing a mixture of thistle and white dandelion seedling extract as an active ingredient. The pharmaceutical composition and the health functional food composition containing the mixture of the thistle and the white dandelion seed extract according to the present invention as an active ingredient are excellent in the effect of inhibiting the activity of GOT and GPT, It is useful for prevention, improvement or treatment of alcoholic liver damage by reducing necrosis and degeneration. It is also useful for preventing, ameliorating or treating alcoholic gastritis by excelling in reduction of oxidative stress and inflammation of alcohol induced gastric tissue.
본 발명에서 사용되는 용어는 다음과 같이 정의된다.The terms used in the present invention are defined as follows.
용어 “약학적 조성물(pharmaceutical composition)”은 본 발명의 엉겅퀴와 흰민들레 전초 추출물의 혼합물에 희석제 또는 담체와 같은 다른 화학 성분들을 혼합한 혼합물을 의미한다.The term " pharmaceutical composition " means a mixture of a mixture of thistle and white dandelion outpost extract of the present invention with other chemical components such as diluent or carrier.
용어 “담체(carrier)”는 세포 또는 조직 내로의 화합물의 부가를 용이하게 하는 화합물로 정의된다. 예를 들어, 디메틸술폭사이드(DMSO)는 생물체의 세포 또는 조직 내로의 많은 유기 화합물들의 투입을 용이하게 하는 통상 사용되는 담체이다.The term " carrier " is defined as a compound that facilitates the addition of a compound into a cell or tissue. For example, dimethylsulfoxide (DMSO) is a commonly used carrier that facilitates the introduction of many organic compounds into cells or tissues of an organism.
용어 “희석제(diluent)”는 대상 화합물의 생물학적 활성 형태를 안정화시킬 뿐만 아니라, 화합물을 용해시키게 되는 물에서 희석되는 화합물로 정의된다. 버퍼 용액에 용해되어 있는 염은 당해 분야에서 희석제로 사용된다. 통상 사용되는 버퍼 용액은 포스페이트 버퍼 식염수이며, 이는 인간 용액의 염 상태를 모방하고 있기 때문이다. 버퍼 염은 낮은 농도에서 용액의 pH를 제어할 수 있기 때문에, 버퍼 희석제가 화합물의 생물학적 활성을 변형하는 일은 드물다.The term " diluent " is defined as a compound that not only stabilizes the biologically active form of the compound of interest, but also dilutes in water to which the compound is dissolved. Salts dissolved in buffer solutions are used as diluents in the art. A commonly used buffer solution is phosphate buffered saline, since it mimics the salt state of the human solution. Since buffer salts can control the pH of the solution at low concentrations, buffer diluents rarely modify the biological activity of the compounds.
용어 “치료”는 이롭거나 바람직한 임상적 결과를 수득하기 위한 접근을 의미한다. 본 발명의 목적을 위해서, 이롭거나 바람직한 임상적 결과는 비제한적으로, 증상의 완화, 질병 범위의 감소, 질병 상태의 안정화(즉, 악화되지 않음), 질병 진행의 지연 또는 속도의 감소, 질병 상태의 개선 또는 일시적 완화 및 경감 (부분적이거나 전체적으로), 검출가능하거나 또는 검출되지 않거나의 여부를 포함한다. 또한, “치료”는 치료를 받지 않았을 때 예상되는 생존율과 비교하여 생존율을 늘이는 것을 의미할 수도 있다. “치료”는 치료학적 치료 및 예방적 또는 예방조치 방법 모두를 가리킨다. 상기 치료들은 예방되는 장애뿐만 아니라 이미 발생한 장애에 있어서 요구되는 치료를 포함한다. 질병을 “완화(alleviating)”하는 것은 치료를 하지 않은 경우와 비교하여, 질병상태의 범위 및/또는 바람직하지 않은 임상적 징후가 감소되거나 및/또는 진행의 시간적 추이(time course)가 늦춰지거나 길어지는 것을 의미한다.The term " treatment " means an approach to obtaining beneficial or desired clinical results. For purposes of the present invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, reduction in the extent of disease, stabilization (i.e., not worsening) of the disease state, (Either partially or totally), detectable or undetected, whether or not an improvement or temporary relief or reduction Also, " treatment " may mean increasing the survival rate compared to the expected survival rate when not receiving treatment. &Quot; Treatment " refers to both therapeutic treatment and prophylactic or preventative measures. Such treatments include treatments required for disorders that have already occurred as well as disorders to be prevented. "Alleviating" a disease may result in a reduction in the extent of the disease state and / or undesirable clinical symptoms and / or a slower or longer time course of the progression, It means to lose.
본 발명에서 사용되는 모든 기술용어는, 달리 정의되지 않는 이상, 본 발명의 관련 분야에서 통상의 당업자가 일반적으로 이해하는 바와 같은 의미로 사용된다. 또한 본 명세서에는 바람직한 방법이나 시료가 기재되나, 이와 유사하거나 동등한 것들도 본 발명의 범주에 포함된다.All technical terms used in the present invention are used in the sense that they are generally understood by those of ordinary skill in the relevant field of the present invention unless otherwise defined. Also, preferred methods or samples are described in this specification, but similar or equivalent ones are also included in the scope of the present invention.
본 발명은 엉겅퀴(Cirsium japonicum) 및 흰민들레(Taraxacum coreanum) 전초 추출물의 혼합물을 유효성분으로 함유하는 알코올성 간 손상의 예방 또는 치료용 약학적 조성물을 제공한다.The present invention relates to a method for the treatment of cirsium japonicum ) and white dandelion ( Taraxacum The present invention also provides a pharmaceutical composition for prevention or treatment of alcoholic liver damage containing a mixture of coreanum extract.
또한, 본 발명은 엉겅퀴와 흰민들레 전초 추출물의 혼합물을 유효성분으로 함유하는 알코올성 간 손상의 예방 또는 개선용 건강기능식품을 제공한다.The present invention also provides a health functional food for preventing or ameliorating an alcoholic liver injury containing a mixture of thistle and white dandelion seed extract as an active ingredient.
본 발명에서 사용된 엉겅퀴(Cirsium japonicum)는 국화과의 여러해살이풀로 연한 식물체와 어린순은 나물로 먹고 성숙한 뿌리는 약으로 쓴다. 약효는 지혈작용이 현저하여 소변출혈, 대변출혈, 코피, 자궁출혈, 외상출혈에 활용된다. 본 발명에서는 엉겅퀴의 전초를 원료로 하여 추출물을 제조하였다.The thistle used in the present invention (Cirsium japonicum ) is a perennial plant of the Asteraceae family. The plant is eaten as a herb and the mature root is a medicine. The drug efficacy is remarkable in hemostatic effect, and it is used for urine hemorrhage, fecal hemorrhage, nosebleed, uterine hemorrhage, trauma hemorrhage. In the present invention, an extract was prepared from thistle seeds as a raw material.
본 발명에서 사용된 흰민들레(Taraxacum coreanum)는 국화과(compositae)에 속한 다년초로 한방에서는 전초를 건조한 것을 봄과 여름에 꽃이 피기 전이나 후에 채취하여 청열해독, 소염, 이뇨의 목적으로 하는 약물로 이용되어 왔다. 본 발명에서는 흰민들레의 전초를 원료로 하여 추출물을 제조하였다.The taraxacum coreanum used in the present invention is a perennial plant belonging to the genus Chrysanthemum (Compositae). It is a drug for the purpose of detoxification, anti-inflammation and diuretic, Have been used. In the present invention, an extract was prepared from the outpast of white dandelion as a raw material.
본 발명의 엉겅퀴와 흰민들레는 상업적으로 판매되는 것을 구입하여 사용하거나, 자연에서 직접 채취 또는 재배한 것을 사용할 수 있다.The thistle and the white dandelion of the present invention may be commercially purchased or used, or may be directly harvested or cultivated.
본 발명의 바람직한 일실시예에서는 엉겅퀴와 흰민들레 전초 추출물을 혼합하여 사용하였다. 상기 엉겅퀴와 흰민들레 전초 추출물을 제조하는 방법은 정치 추출법, 초음파 추출법, 여과법 및 환류 추출법 등 당업계의 통상적인 추출방법을 사용할 수 있다. 바람직하게는 세척 및 건조로 이물질이 제거된 엉겅퀴와 흰민들레 전초를 동결건조한 후 분쇄하여 추출용매로 3회 반복하여 정치 추출하였다. 상기 추출용매는 당업계의 통상적인 추출용매라면 제한없이 사용할 수 있고, 바람직하게는 물, C1~C4의 알코올 또는 이들의 혼합용매일 수 있으며, 보다 바람직하게는 메탄올 또는 에탄올일 수 있고, 가장 바람직하게는 99% 에탄올일 수 있다. 필요한 경우에는 당업계에 공지된 방법에 따라 여과, 농축 및 동결건조 등의 단계를 추가적으로 거쳐 분말로 제조될 수 있다.In a preferred embodiment of the present invention, thistle and white dandelion outpost extract were mixed and used. The method for preparing the thistle and the white dandelion seedling extract may be a conventional extraction method such as a stationary extraction method, an ultrasonic extraction method, a filtration method and a reflux extraction method. Preferably, the thistle and the white dandelion outpost, which have been freed from foreign matter by washing and drying, are lyophilized, pulverized, and extracted three times with an extraction solvent. The extraction solvent may be any conventional extraction solvent in the art, and may be water, C 1 -C 4 alcohol or a mixture thereof, more preferably methanol or ethanol, Most preferably 99% ethanol. If necessary, the powder may be further subjected to steps such as filtration, concentration and freeze-drying according to methods known in the art.
간과 관련된 여러 질환들을 감별하기 위해서는 몇 가지 화학적 검사들을 종합적으로 해석하는 것이 필요한데, 이를 위하여 몇 가지 검사항목들을 묶어 간 기능 검사로 통칭한다. 주요 검사로는 GOT, GPT 등이 있고, 이외에도 총 단백질, 알부민, 암모니아 등의 항목을 더하여 검사하는 경우도 많다.In order to distinguish the various diseases related to the liver, it is necessary to comprehensively analyze several chemical tests. For this purpose, some test items are collectively referred to as liver function tests. Major tests include GOT and GPT. In addition, there are many cases in which total protein, albumin, and ammonia are added to the test.
GOT(glutamic oxaloacetic transaminase, 아스파르트산 아미노기전달효소)는 L-아스파르트산의 아미노기를 α-케토글루타르산으로 전달하여 옥살로아세트산과 L-글루탐산을 생성하는 가역반응을 촉매하는 효소이다. 간염, 심근경색 등의 진단 시 혈중에서의 이 효소 활성에 대한 측정이 자주 이용된다.GOT (glutamic oxaloacetic transaminase) is an enzyme that catalyzes the reversible reaction of producing oxaloacetic acid and L-glutamic acid by transferring the amino group of L-aspartic acid to? -Ketoglutaric acid. In the diagnosis of hepatitis and myocardial infarction, measurement of this enzyme activity in the blood is frequently used.
GPT(glutamic-pyruvic transaminase, 알라닌 아미노기전달효소)는 알라닌의 아미노기를 α-케토글루타르산에 전달하여 피루브산과 글루탐산 생성반응을 촉매하는 효소이다. 간·담도계 질환의 진단을 위해 혈액 중의 이 효소의 활성 측정이 자주 이루어진다.GPT (glutamic-pyruvic transaminase) is an enzyme that catalyzes pyruvic acid and glutamic acid production by transferring the amino group of alanine to α-keto glutaric acid. In order to diagnose liver and biliary system diseases, the activity of this enzyme in blood is frequently measured.
따라서, 본 발명에서는 알코올성 간 손상 개선 효과를 GOT 및 GPT 수치 측정을 통해 확인하였다. 본 발명의 엉겅퀴와 흰민들레 전초 추출물을 함유하는 조성물은 알코올, 바람직하게는 에탄올 투여로 증가된 GOT 및 GPT 수치를 현저하게 저해할 수 있고(도 1), 증가된 간 조직의 무게를 감소시킬 수 있다(도 2). 또한 에탄올로 손상된 간 조직의 간세포 괴사(hepatocyte necrosis)와 변성(degeneration), 지방변성(fatty change), 염증 세포 침윤(inflammatory cell infiltration) 및 간세포의 세포질 공포화(cytoplasmic vacuolation of hepatocyte)를 완화시켜 알코올성 간 손상을 효과적으로 개선시킬 수 있음을 확인하였다(도 3).Therefore, in the present invention, the improvement effect of alcoholic liver damage was confirmed by measuring the GOT and GPT values. The compositions containing the thistle and white dandelion outpost extract of the present invention can significantly inhibit increased GOT and GPT levels from alcohol, preferably ethanol administration (Fig. 1), and can reduce the weight of the increased liver tissue (Fig. 2). In addition, hepatocyte necrosis, degeneration, fatty change, inflammatory cell infiltration, and cytoplasmic vacuolation of hepatocyte of hepatocyte necrosis damaged by ethanol are alleviated, Liver damage can be effectively improved (Fig. 3).
본 발명의 조성물에 있어서, 엉겅퀴와 흰민들레 전초 추출물은 알코올성 간 손상을 치료하기 위한 최적의 효과를 나타내기 위해 특정 중량비로 혼합될 수 있다. 바람직한 혼합 중량비는 1:0.25 내지 1:1이며, 가장 바람직한 혼합 중량비는 1:0.25일 수 있다. 엉겅퀴와 흰민들레 전초 추출물을 상기 범위를 벗어난 중량비로 혼합할 경우, 두 가지 추출물의 복합 상승효과가 감소하여 최적의 활성을 나타낼 수 없으므로(도 1 내지 3), 상기 중량비 범위 내에서 두 가지 추출물을 혼합하는 것이 바람직하다.In the composition of the present invention, thistle and white dandelion outpost extract may be mixed in a specific weight ratio to exhibit optimal effects for treating alcoholic liver damage. The preferred mixing weight ratio is 1: 0.25 to 1: 1, and the most preferred mixing weight ratio can be 1: 0.25. When the thistle and white dandelion seedling extracts were mixed at a weight ratio out of the above range, the complex synergistic effect of the two extracts was reduced and the optimum activity could not be exhibited (Figs. 1 to 3) Mixing is preferred.
나아가, 본 발명은 엉겅퀴(Cirsium japonicum) 및 흰민들레(Taraxacum coreanum) 전초 추출물의 혼합물을 유효성분으로 함유하는 알코올성 위염의 예방 또는 치료용 약학적 조성물을 제공한다.Furthermore, the present invention thistle (Cirsium japonicum ) and white dandelion ( Taraxacum The present invention provides a pharmaceutical composition for preventing or treating alcoholic gastritis containing as an active ingredient a mixture of a coreanum extract.
본 발명은 또한, 엉겅퀴와 흰민들레 전초 추출물의 혼합물을 유효성분으로 함유하는 알코올성 위염의 예방 또는 개선용 건강기능식품 조성물을 제공한다.The present invention also provides a health functional food composition for preventing or alleviating an alcoholic gastritis containing a mixture of thistle and white dandelion seed extract as an active ingredient.
상기 조성물에서 엉겅퀴와 흰민들레 전초 추출물에 대한 설명은 전술한 바와 동일하므로, 중복 기재에 따른 본 명세서의 과도한 복잡성을 피하기 위하여 그 기재를 생략한다.The description of thistle and white dandelion outpost extract in the composition is the same as that described above, so that the description thereof is omitted in order to avoid the excessive complexity of the present specification according to the overlapping description.
본 발명의 바람직한 일실시예에서는, 본 발명의 엉겅퀴와 흰민들레 전초 추출물의 혼합물을 함유하는 조성물의 알코올성 위염 개선 효과를 확인하기 위해 알코올, 바람직하게는 에탄올 투여로 증가된 산화적 스트레스의 개선 효과를 활성산소종을 측정함으로써 확인하였다. 본 발명의 엉겅퀴와 흰민들레 전초 추출물의 혼합물을 함유하는 조성물은 증가된 활성산소종의 수준을 정상군과 유사한 정도로 감소시켜 알코올에 의해 위 조직에서 증가된 산화스트레스를 매우 효과적으로 감소시켰다(도 4). 또한, 알코올로 유발된 위 조직의 염증을 현저하게 완화시켜 알코올성 위염 완화에 탁월한 효능이 있음을 확인하였다(도 5).In a preferred embodiment of the present invention, in order to confirm the effect of improving the alcoholic gastritis of the composition containing the mixture of thistle and white dandelion seed extract of the present invention, the effect of improving the oxidative stress increased by the administration of alcohol, preferably ethanol, And was confirmed by measuring the active oxygen species. The composition containing the mixture of thistle and white dandelion outpost extract of the present invention reduced the level of the increased active oxygen species to a similar level to that of the normal group, thereby effectively reducing the increased oxidative stress in the stomach tissue by alcohol (Fig. 4) . In addition, it was confirmed that the inflammation of the stomach tissue induced by alcohol was remarkably alleviated to exert an excellent effect in alleviating alcoholic gastritis (FIG. 5).
본 발명의 조성물에 있어서, 엉겅퀴와 흰민들레 전초 추출물은 알코올성 위염을 치료하기 위한 최적의 효과를 나타내기 위해 특정 중량비로 혼합될 수 있다. 바람직한 혼합 중량비는 1:0.25 내지 1:4이며, 더욱 바람직하게는 1:1 내지 1:4이며, 가장 바람직한 혼합 중량비는 1:4일 수 있다. 엉겅퀴와 흰민들레 전초 추출물을 상기 범위를 벗어난 중량비로 혼합할 경우, 두 가지 추출물의 복합 상승효과가 감소하여 최적의 활성을 나타낼 수 없으므로(도 4 및 5), 상기 중량비 범위 내에서 두 가지 추출물을 혼합하는 것이 바람직하다.In the composition of the present invention, thistle and white dandelion outpost extract may be mixed at specific weight ratios to exhibit optimal effects for treating alcoholic gastritis. The preferred mixing weight ratio is 1: 0.25 to 1: 4, more preferably 1: 1 to 1: 4, and most preferably 1: 4. When the thistle and white dandelion seedling extracts were mixed at a weight ratio out of the above range, the complex synergistic effect of the two extracts was reduced and the optimum activity could not be exhibited (FIGS. 4 and 5) Mixing is preferred.
본 발명의 약학적 조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.The pharmaceutical compositions of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions.
본 발명에 따른 약학적 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다.The pharmaceutical composition according to the present invention can be formulated in the form of oral, granule, tablet, capsule, suspension, emulsion, syrup, aerosol or the like oral preparation, external preparation, suppository and sterilized injection solution according to a conventional method Can be used.
본 발명의 조성물에 함유될 수 있는 담체, 부형제 및 희석제로는 락토오즈(lactose), 덱스트로즈, 수크로스(sucrose), 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다.Examples of carriers, excipients and diluents that may be contained in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin , Calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다.In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used.
경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 화합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스 또는 락토오스, 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose or lactose , Gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included .
비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. As a base for suppositories, witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like can be used.
상기 본 발명의 약학적 조성물은 약제학적으로 유효한 양으로 투여한다.The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.
본 발명에서 용어 "약제학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효 용량 수준은 개체 종류 및 중증도, 연령, 성별, 감염된 바이러스 종류, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래의 치료제와는 순차적 또는 동시에 투여될 수 있다. 그리고 단일 또는 다중 투여될 수 있다. 상기 요소를 모두 고려하여 부작용없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 당업자에 의해 용이하게 결정될 수 있다.The term "pharmaceutically effective amount " as used herein means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level will vary depending on the species and severity, age, sex, , The activity of the drug, the sensitivity to the drug, the time of administration, the route of administration and rate of release, the duration of the treatment, factors including co-administered drugs, and other factors well known in the medical arts. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. And can be administered singly or multiply. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without adverse effect, and can be easily determined by those skilled in the art.
본 발명의 약학적 조성물은 단순포진바이러스 감염의 예방 또는 치료를 위하여 단독으로, 또는 수술, 호르몬 치료, 약물 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다.The pharmaceutical composition of the present invention can be used alone or in combination with methods for the prevention or treatment of herpes simplex virus infection or using surgery, hormone therapy, drug therapy and biological response modifiers.
상기 조성물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁 내 경막 또는 뇌혈관 내 주사에 의해 투여될 수 있다.The composition can be administered to mammals such as rats, mice, livestock, humans, and the like in a variety of routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine dural or intracerebral injection.
본 발명의 엉겅퀴와 흰민들레 전초 추출물의 혼합물을 식품 첨가물로 사용할 경우, 상기 혼합물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 혼합량은 사용 목적 (예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조 시에는 본 발명의 조성물은 원료에 대하여 0.01 ~ 10 중량%, 바람직하게는 0.05 ~ 1 중량%의 양으로 첨가된다. 그러나 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하로도 사용될 수 있다.When the mixture of thistle and white dandelion outpost extract of the present invention is used as a food additive, the mixture can be used as it is, or can be used together with other food or food ingredients, and can be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or therapeutic treatment). Generally, in the production of food or beverage, the composition of the present invention is added in an amount of 0.01 to 10% by weight, preferably 0.05 to 1% by weight based on the raw material. However, in the case of long-term ingestion intended for health and hygiene purposes or for the purpose of controlling health, the amount can also be used in the above-mentioned range.
상기 건강기능식품은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 천연 과일 주스 및 과일 주스 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 또한, 건강기능식품은 육류, 소세지, 빵, 초콜릿, 캔디류, 스넥류, 과자류, 피자, 라면, 껌류, 아이스크림류, 스프, 음료수, 차, 기능수, 드링크제, 알코올 및 비타민 복합제 중 어느 하나의 형태일 수 있다.The health functional food may contain flavoring agents such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and thickening agents (cheese, chocolate etc.), pectic acid and its salts, alginic acid and its salts, Organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. It can also contain natural fruit juices and pulp for the production of fruit juices and vegetable drinks. These components may be used independently or in combination. The health functional food may be any one of meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, gum, ice cream, soup, beverage, tea, functional water, drink, alcohol and vitamin .
본 발명의 건강 음료 조성물은 엉겅퀴와 흰민들레 전초 추출물의 혼합물을 함유하는 것 외에는 액체성분에는 특별한 제한은 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다.The health beverage composition of the present invention is not particularly limited to a liquid ingredient except that it contains a mixture of thistle and white dandelion outpost extract, and may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages.
또한, 상기 건강기능식품은 식품첨가물을 추가로 포함할 수 있으며, “식품첨가물”로서의 적합여부는 다른 규정이 없는 한 식품의약품안정청에 승인된 식품첨가물공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다.In addition, the health functional food may further include food additives, and the suitability of the food functional food as a " food additive " is not limited to the corresponding items in general rules and general test methods approved by the Food and Drug Administration Shall be determined according to the relevant standards and standards.
상기 “식품첨가물공전”에 수재된 품목으로 예를 들어, 케톤류, 글리신, 구연산 칼륨, 니코틴산, 계피산 등의 화학적 합성품, 감색소, 감초추출물, 결정셀룰로오스, 고랭색소, 구아검 등의 천연첨가물, L-글루타민산나트륨제제, 면류첨가알칼리제, 보존료제제, 타르색소제제 등의 혼합 제제류 등을 들 수 있다.Examples of the products that have been used in the above-mentioned "food additives" include natural products such as ketones, chemical products such as glycine, potassium citrate, nicotinic acid and cinnamic acid, sensory coloring matter, licorice extract, crystalline cellulose, high- - Mixed preparations such as a sodium glutamate preparation, a noodle-added alkaline agent, a preservative preparation, a tar coloring agent and the like.
하기의 실시예를 통하여 본 발명을 더욱 구체적으로 설명하기로 하지만, 하기의 실시예가 본 발명의 범위를 제한하는 것은 아니며, 이는 본 발명의 이해를 돕기 위한 것으로 해석되어야 할 것이다.The present invention will now be described more specifically with reference to the following examples. However, the following examples should not be construed as limiting the scope of the present invention, but should be construed to facilitate understanding of the present invention.
1-1. 엉겅퀴와 1-1. Thistle 흰민들레White dandelion 전초outpost 추출물의 제조 Preparation of extract
수확한 엉겅퀴(Cirsium japonicum)와 흰민들레(Taraxacum coreanum)의 꽃과 뿌리를 제거한 전초를 물로 세척하고 동결건조기(Martin Christ, Osterode, Germany)로 동결건조하였다. 동결건조된 시료를 분쇄 후 99% 에탄올(EtOH)로 실온에서 24시간 3회 반복하여 정치추출하였다. 추출물은 여과지(Filter paper, No.4)를 이용하여 여과하고, 여과된 추출물은 회전감압농축기(Heidolph, Germanay)로 45℃에서 감압농축하였다. 농축물은 동결건조 후 분말형태로 수득하였다. Cirsium with harvested thistle japonicum ) and taraxacum coreanum were washed with water and lyophilized with a freeze dryer (Martin Christ, Osterode, Germany). The lyophilized sample was pulverized and then subjected to repeated extraction with 99% ethanol (EtOH) at room temperature for 24 hours three times. The extract was filtered using a filter paper (No. 4), and the filtered extract was concentrated under reduced pressure at 45 ° C with a rotary evaporator (Heidolph, Germanay). The concentrate was obtained as a powder after lyophilization.
1-2. 1-2. 실험 동물Experimental animal
6 주령 된 C57BL/6 수컷 마우스를 (주)중앙실험동물로부터 구입하였다. 22℃에서 명/암 주기를 12시간 간격으로 설정하고, 식이와 물을 자유롭게 공급하여 1 주일간 기본식이로 적응시켰다.Six-week-old C57BL / 6 male mice were purchased from the Central laboratory animals. The light / dark cycle was set at 12 hours at 22 ° C, and the diet and water were freely fed and adapted to the basic diet for one week.
알코올성 간 손상 개선 효과의 확인Identification of Alcoholic Liver Damage Improvement Effect
2-1. 2-1. 실험군Experimental group 설정 및 시료 투여 Setting and sample administration
상기 실시예 1-2의 실험동물을 각 군당 5마리씩, 아무것도 처리하지 않은 정상군, 5.0g/kg의 에탄올만을 투여한 대조군, 및 5.0g/kg의 에탄올에 용해된 각각의 실험시료를 투여한 5개의 실험군으로 나누어 실험을 진행하였다. 각 실험군에 투여된 실험시료는 하기 표 1에 기재된 바와 같다. 에탄올에 용해된 실험시료는 12시간마다 200mg/kg씩 3회 경구투여 하였고, 대조군에는 에탄올만을 12시간마다 3회 경구투여 하였다. 실험기간 동안 물과 식이는 자유롭게 공급하였고, 실험시료(엉겅퀴 추출물과 흰민들레 추출물)는 매일 동일한 시간에 경구 투여하였다. 마지막 경구투여 24시간 후 에테르 마취하여 개복 후 심장채혈 및 간 조직과 위조직을 적출하였다.The experimental animals of Example 1-2 were injected with 5 mice per group, a normal group without any treatment, a control group with 5.0 g / kg of ethanol alone, and each experimental sample dissolved in 5.0 g / kg of ethanol The experiment was divided into five experimental groups. The experimental samples administered to each experimental group are as shown in Table 1 below. Experimental samples dissolved in ethanol were orally administered three times at 200 mg / kg every 12 hours, and the control group was orally administered only three times every 12 hours. Water and diet were freely supplied during the experiment, and experimental samples (thistle extract and white dandelion extract) were orally administered at the same time every day. Twenty-four hours after the last oral administration, ether anesthesia was performed, and then the heart was harvested and liver tissues and stomach tissues were extracted.
실험군
Experimental group
추출물Thistle outpost
extract
추출물White dandelion outpost
extract
2-2. 혈청 2-2. serum 중 간middle 기능 지표효소 활성 측정 Functional indicator Enzyme activity measurement
제조사의 지시에 따라 진단 키트(Procedure No. 505, Sigma Chemical Co., St Louis, MO)를 사용하여 비색법으로(colorimetrically) GOT (glutamic oxaloacetic transaminase) 및 GPT (glutamic-pyruvic transaminase) 활성을 측정하였다.Glutamic oxaloacetic transaminase (GOT) and glutamic-pyruvic transaminase (GPT) activity were measured colorimetrically using a diagnostic kit (Procedure No. 505, Sigma Chemical Co., St Louis, MO) according to the manufacturer's instructions.
그 결과, 도 1(A) 및 (B)에 나타난 바와 같이 에탄올 투여로 GOT 및 GPT 수치(대조군)가 증가하였고, 엉겅퀴와 흰민들레 전초 추출물을 각각 단독으로 투여한 군에서는 GOT 및 GPT 수치가 감소되었으나 정상군 수준에는 미치지 못했다. 이에 반해, 엉겅퀴와 흰민들레 전초 추출물이 1:0.25 및 1:1 중량비로 혼합된 혼합물 A군 및 혼합물 B군은 대조군에 비해 GOT 및 GPT 수치가 현저하게 감소하였으며, 특히 혼합물 A군은 엉겅퀴와 흰민들레 전초 추출물을 각각 단독으로 투여한 군 보다 GOT 및 GPT 수치를 효과적으로 감소시켜 정상군 수준과 유사한 수준으로 간수치가 회복됨을 확인하였다. 이러한 혼합물 상승효과는 엉겅퀴와 흰민들레 전초추출물을 1:0.25의 중량비로 혼합하였을 때 가장 극대화됨을 알 수 있다.As a result, as shown in Figs. 1 (A) and (B), the GOT and GPT values (control group) were increased by ethanol administration and the GOT and GPT values were decreased in the group administered with thistle and white dandelion seed extract But it did not reach the normal level. Compared with the control group, the concentrations of GOT and GPT in the mixtures A and B, in which 1: 0.25 and 1: 1 weight ratio of thistle and white dandelion seeds extracts were mixed, The results showed that GOT and GPT levels were reduced more effectively than those treated with dandelion seedlings alone. The synergistic effect of this mixture is maximized when thistle and white dandelion outpost extract are mixed at a weight ratio of 1: 0.25.
2-3. 간 무게 측정2-3. Liver weighing
적출된 간 무게를 측정한 결과, 도 2에 나타난 바와 같이 체중(100g) 당 간 무게는 에탄올 투여에 의해 통계적으로 유의하게 증가하였다(대조군). 엉겅퀴 전초 추출물 투여군, 혼합물 A 투여군 및 혼합물 B 투여군은 에탄올에 의해 증가된 간 무게를 유의적으로 감소시켰고, 이들 중 혼합물 A 투여군의 간 무게 감소 효과가 가장 우수하였다. 특히, 혼합물 A군의 경우, 에탄올에 의해 증가된 간 무게를 정상군 수준으로 감소시켰다. 이러한 효과는 엉겅퀴와 흰민들레 전초 추출물을 각각 단독으로 투여한 군 보다 개선된 것으로, 엉겅퀴 전초 추출물과 흰민들레 전초 추출물을 1:0.25의 중량비로 혼합하였을 때 혼합물 상승효과가 가장 극대화됨을 알 수 있다.As shown in FIG. 2, liver weight per body weight (100 g) was statistically significantly increased by ethanol administration (control group). The effects of thistle outpost extract, mixture A, and mixture B on ethanol - induced liver weight were significantly decreased. Especially, in the case of mixture A group, the liver weight increased by ethanol was reduced to the normal group level. These effects were more improved than those of the thistle and white dandelion outpost extracts alone, and the synergistic effect of the mixture was maximized when the thistle outpost extract and white dandelion outpost extract were mixed at a weight ratio of 1: 0.25.
2-4. 간 조직 검사2-4. Liver biopsy
간 조직을 ~3mm 두께의 얇은 조각(slice)으로 자르고 10% 중화 포르말린으로 고정하고, 조직 조각을 파라플라스트(paraplast)에 포매하였다. 5μm의 조직 조각을 H&E(hematoxylin and eosin)으로 염색하고 Nikon Eclipse E400 광학 현미경으로 관찰하였다.Liver tissue was cut into ~ 3 mm thick slices, fixed with 10% neutralized formalin, and tissue pieces embedded in paraplast. Tissue pieces of 5 mu m were stained with H & E (hematoxylin and eosin) and observed with a Nikon Eclipse E400 optical microscope.
그 결과, 도 3에 나타난 바와 같이 에탄올만 투여한 군의 마우스 간 조직은 괴사와 함께 미세소포성 지방증(microvesicular steatosis)이 두드러지게 나타나 간 조직이 손상되었음을 확인하였다. 이러한 알코올성 간 손상은 엉겅퀴 전초 추출물 투여군, 혼합물 A, B 및 C 투여군에서 개선되었고, 특히, 엉겅퀴와 흰민들레 전초 추출물을 1:0.25의 중량비로 혼합한 혼합물 A군에서 가장 현저하게 개선되었다. 간 조직 검사에서도 마찬가지로 엉겅퀴와 흰민들레 전초 추출물을 1:0.25의 중량비로 혼합하였을 때 혼합물 상승효과가 가장 두드러지게 나타남을 확인하였다.As a result, as shown in FIG. 3, it was confirmed that mouse liver tissue of ethanol-only group showed prominent microvesicular steatosis together with necrosis, and liver tissue was damaged. These alcoholic liver injuries were improved in thistle outpost extract group, mixture A, B and C administration group, and most remarkably improved in mixture A group in which thistle and white dandelion outpost extract were mixed at a weight ratio of 1: 0.25. The liver biopsy showed that the synergistic effect was most pronounced when the thistle and white dandelion outpost extracts were mixed at a weight ratio of 1: 0.25.
이상의 실험 결과를 통해, 엉겅퀴와 흰민들레 전초 추출물이 1:0.25 내지 1:1의 중량비로 혼합된 혼합물이 알코올성 간 손상을 치료하는데 매우 유용함을 확인하였다.From the above results, it was confirmed that a mixture of thistle and white dandelion seedling extract at a weight ratio of 1: 0.25 to 1: 1 is very useful for treating alcoholic liver damage.
알코올성 위염 개선 효과의 확인Identification of alcoholic gastritis improvement
3-1. 위 조직의 3-1. Above 산화적Oxidative 스트레스 개선 Stress Improvement
상기 실시예 2-1에서 적출한 위 조직 내 산화적 스트레스를 ROS(reactive oxidative species)를 이용하여 측정하였다. 위 조직은 1 mM EDTA-50 mM 소듐 포스페이트 버퍼(pH 7.4)를 이용하여 분쇄한 후 ROS를 측정하기 위하여 25 mM DCFH-DA를 혼합하였다. 그 다음 형광 광도계를 이용하여 0분부터 매 10분씩 530 nm의 방출 파장(emission wavelength)과 486nm의 여기 파장(excitation wavelength)에서 30분간 측정한 산출 값을 계산하였다.The oxidative stress in the stomach tissues extracted in Example 2-1 was measured using ROS (reactive oxidative species). The stomach tissue was pulverized with 1 mM EDTA-50 mM sodium phosphate buffer (pH 7.4) and 25 mM DCFH-DA was mixed to measure ROS. Then, using a fluorescence spectrophotometer, the emission value measured at 530 nm and the excitation wavelength at 486 nm for 30 minutes was calculated every 10 minutes from 0 minutes.
그 결과, 도 4에 나타난 바와 같이 에탄올만을 투여한 대조군은 정상군에 비해 ROS 수치가 증가하였고 엉겅퀴 전초 추출물 또는 흰민들레 전초 추출물을 단독으로 투여한 군에서는 ROS 수치가 유의적으로 감소하였다. 특히 혼합물 A, B 및 C 투여군은 각각 상기 단독 투여군보다 ROS 수치가 더욱 감소하여 정상군 수준에 도달하였고, 혼합물 A와 혼합물 C 투여군의 경우 혼합물 상승 효과로 인해 산화적 스트레스 감소가 두드러지게 나타났다.As a result, as shown in FIG. 4, the ROS level of the control group treated with ethanol alone was increased compared to that of the normal group, and the ROS level was significantly decreased in the group administered with thistle outpost extract or white dandelion outpost extract alone. In particular, the ROS levels of the mixtures A, B and C were lower than those of the single administration group, and the concentrations of the mixture reached to the normal level. In the case of mixture A and mixture C, oxidative stress decreased remarkably due to synergistic effect.
3-2. 위 조직의 염증 개선3-2. Improved inflammation of stomach tissue
각 군에서 적출한 위 조직을 고정하여 손상된 범위 및 손상 정도를 관찰하였다. 그 결과, 도 5에 나타난 바와 같이 에탄올만 투여한 대조군의 경우, 위 조직의 염증, 출혈, 발적 및 부종이 발생하였고 손상 부위 면적 또한 매우 넓었다. 이러한 위 조직 손상은 혼합물 B 및 C 투여군에서 눈에 띄게 회복되었으며, 특히 다른 실험군들에 비해 엉겅퀴 전초 추출물과 흰민들레 전초 추출물이 1:4의 중량비로 혼합된 혼합물 C군에서 상승 효과가 최대로 나타나 위 조직 손상이 극적으로 완화되어 정상군 수준으로 회복됨을 확인하였다.The stomach tissues extracted from each group were fixed and the degree of damage and degree of damage were observed. As a result, as shown in FIG. 5, in the control group in which only ethanol was administered, inflammation, hemorrhage, erythema and edema occurred in the stomach tissue and the area of the damaged area was also very wide. These stomach injuries were remarkably recovered in the mixtures B and C, and the synergistic effect was maximized in the mixture C, in which the thistle outpost extract and the white dandelion outpost extract were mixed at a weight ratio of 1: 4, It was confirmed that the stomach injuries were dramatically relieved and recovered to normal levels.
이상의 실험 결과를 통해, 엉겅퀴와 흰민들레 전초 추출물이 1:0.25 내지 1:4, 바람직하게는 1:1 내지 1:4의 중량비로 혼합된 혼합물이 알코올성 위염을 치료하는데 매우 유용함을 확인하였다.From the above experimental results, it was confirmed that the mixture of thistle and white dandelion seedling extract at a weight ratio of 1: 0.25 to 1: 4, preferably 1: 1 to 1: 4 is very useful for treating alcoholic gastritis.
제조예Manufacturing example 1: 약학적 제제의 제조 1: Preparation of pharmaceutical preparations
1-1. 1-1. 산제의Sanje 제조 Produce
엉겅퀴 전초 추출물 2g과 흰민들레 전초 추출물 0.5g의 혼합물 또는 엉겅퀴 전초 추출물 0.5g과 흰민들레 전초 추출물 2g의 혼합물을 유당 1g과 혼합한 후, 기밀포에 충진하여 산제를 제조하였다.A mixture of 2 g of the thistle outpost extract and 0.5 g of the white dandelion outpost extract or 0.5 g of the thistle outpost extract and 2 g of the white dandelion outpost extract was mixed with 1 g of lactose and filled in airtight bags to prepare a powder.
1-2. 정제의 제조1-2. Manufacture of tablets
엉겅퀴 전초 추출물 100mg과 흰민들레 전초 추출물 25mg의 혼합물 또는 엉겅퀴 전초 추출물 25mg과 흰민들레 전초 추출물 100mg의 혼합물을 옥수수 전분 100 ㎎, 유당 100 ㎎ 및 스테아린산 마그네슘 2 ㎎과 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.The mixture of 100 mg of corn starch, 100 mg of lactose and 2 mg of magnesium stearate was mixed with a mixture of 100 mg of the thistle outpost extract and 25 mg of the white dandelion outpost extract or 25 mg of the thistle outpost extract and 100 mg of the white dandelion outpost extract, To prepare tablets.
1-3. 캡슐제의 제조1-3. Preparation of capsules
엉겅퀴 전초 추출물 2g과 흰민들레 전초 추출물 0.5g의 혼합물 또는 엉겅퀴 전초 추출물 0.5g과 흰민들레 전초 추출물 2g의 혼합물을 옥수수 전분 100 ㎎, 유당 100 ㎎ 및 스테아린산 마그네슘 2 ㎎과 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.A mixture of 2 g of the thistle outpost extract and 0.5 g of the white dandelion seedling extract or 0.5 g of the thistle outpost extract and 2 g of the white dandelion seedling extract were mixed with 100 mg of corn starch, 100 mg of lactose and 2 mg of magnesium stearate, The capsule was packed in a gelatin capsule according to the manufacturing method of the capsule.
1-4. 주사액제의 제조1-4. Injection preparation
적당한 주사용 염화나트륨 BP에 엉겅퀴 전초 추출물 10 ㎍/㎖와 흰민들레 전초 추출물 2.5㎍/㎖의 혼합물 또는 엉겅퀴 전초 추출물 2.5 ㎍/㎖와 흰민들레 전초 추출물 10㎍/㎖의 혼합물을 용해시키고, 생성된 용액의 pH를 묽은염산 BP를 사용하여 pH 3.5로 조절하고, 주사용 염화나트륨 BP(최대 1 ㎖)를 사용하여 용적을 조절하여 충분히 혼합하였다. 용액을 투명 유리로 된 5 ㎖ 타입 I 앰플 중에 충전시키고, 유리를 용해시킴으로써 공기의 상부 격자하에 봉입시키고, 120 ℃에서 15분 이상 오토클래이브시켜 살균하여 주사액제를 제조하였다.A mixture of 10 占 퐂 / ml of thistle outpost extract and 2.5 占 퐂 / ml of a mixture of thistle outpost extract and 2.5 占 퐂 / ml of thistle outpost extract and 10 占 퐂 / ml of white dandelion outpost extract was dissolved in a suitable injectable sodium chloride BP and the resulting solution Was adjusted to pH 3.5 with diluted hydrochloric acid BP and mixed well by adjusting the volume using injectable sodium chloride BP (max. 1 ml). The solution was filled in a 5 ml type I ampoule made of transparent glass, sealed in an upper lattice of air by dissolving the glass, sterilized by autoclaving at 120 DEG C for 15 minutes or longer, and an injection solution was prepared.
제조예Manufacturing example 2: 건강식품의 제조 2: Manufacture of health food
2-1. 조리용 양념의 제조2-1. Manufacture of cooking seasonings
엉겅퀴 전초 추출물과 흰민들레 전초 추출물을 1:0.25 내지 1:4의 중량비로 혼합한 혼합물을 0.2 ~ 10 중량%로 첨가하여 건강 증진용 조리용 양념을 제조하였다.A mixture prepared by mixing the thistle outpost extract and the white dandelion outpour extract at a weight ratio of 1: 0.25 to 1: 4 was added in an amount of 0.2 to 10 wt% to prepare a cooking sauce for health promotion.
2-2. 토마토 2-2. tomato 케찹ketchup 및 소스의 제조 And source
엉겅퀴 전초 추출물과 흰민들레 전초 추출물을 1:0.25 내지 1:4의 중량비로 혼합한 혼합물 0.2 ~ 1.0 중량%를 토마토 케찹 또는 소스에 첨가하여 건강 증진용 토마토 케찹 또는 소스를 제조하였다.A tomato ketchup or sauce for health promotion was prepared by adding 0.2-1.0 wt% of a mixture prepared by mixing thistle outpost extract and white dandelion seed extract at a weight ratio of 1: 0.25 to 1: 4 to tomato ketchup or sauce.
2-3. 밀가루 식품의 제조2-3. Manufacture of flour food products
엉겅퀴 전초 추출물과 흰민들레 전초 추출물을 1:0.25 내지 1:4의 중량비로 혼합한 혼합물 0.1 ~ 5.0 중량%를 밀가루에 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하여 건강 증진용 식품을 제조하였다.Bread, cake, cookies, crackers and noodles were prepared by adding 0.1 to 5.0% by weight of a mixture obtained by mixing thistle outpost extract and white dandelion seedling extract at a weight ratio of 1: 0.25 to 1: 4 to wheat flour Health enhancing foods were prepared.
2-4. 2-4. 스프soup 및 육즙 (gravies)의 제조 And gravies
엉겅퀴 전초 추출물과 흰민들레 전초 추출물을 1:0.25 내지 1:4의 중량비로 혼합한 혼합물 0.1 ~ 1.0 중량%를 스프 및 육즙에 첨가하여 건강 증진용 육가공 제품, 면류의 수프 및 육즙을 제조하였다.0.1-1.0 wt% of a mixture of thistle outpost extract and white dandelion outpost extract at a weight ratio of 1: 0.25 to 1: 4 was added to the soup and juice to prepare health promotion meat product, noodle soup and juice.
2-5. 그라운드 2-5. ground 비프Beef (ground beef)의 제조 manufacture of ground beef
엉겅퀴 전초 추출물과 흰민들레 전초 추출물을 1:0.25 내지 1:4의 중량비로 혼합한 혼합물 10 중량%를 그라운드 비프에 첨가하여 건강 증진용 그라운드 비프를 제조하였다.A ground beef for health promotion was prepared by adding 10% by weight of a mixture obtained by mixing thistle outpost extract and white dandelion seedling extract at a weight ratio of 1: 0.25 to 1: 4 to ground beef.
2-6. 유제품 (dairy products)의 제조2-6. Manufacture of dairy products
엉겅퀴 전초 추출물과 흰민들레 전초 추출물을 1:0.25 내지 1:4의 중량비로 혼합한 혼합물 0.1 ~ 1.0 중량%를 우유에 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.0.1 to 1.0 wt.% Of a mixture obtained by mixing the thistle outpost extract and the white dandelion seedling extract at a weight ratio of 1: 0.25 to 1: 4 was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.
2-7. 2-7. 선식의Solar 제조 Produce
현미, 보리, 찹쌀, 율무를 공지된 방법으로 알파화시켜 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.The brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the powder was prepared into a powder having a particle size of 60 mesh by a pulverizer.
검정콩, 검정깨, 들깨도 공지된 방법으로 쪄서 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.Black beans, black sesame seeds, and perilla seeds were steamed and dried by a known method, and then they were prepared into powders having a particle size of 60 mesh by a pulverizer.
엉겅퀴 전초 추출물과 흰민들레 전초 추출물을 1:0.25 내지 1:4의 중량비로 혼합한 혼합물을 진공 농축기에서 감압농축하고, 분무, 열풍 건조기로 건조하여 얻은 건조물을 분쇄기로 입도 60 메쉬로 분쇄하여 건조분말을 얻었다.The mixture obtained by mixing the thistle outpost extract and the white dandelion seedling extract at a weight ratio of 1: 0.25 to 1: 4 was concentrated under reduced pressure in a vacuum concentrator, sprayed and dried with a hot air drier, and the resulting dried material was pulverized to a particle size of 60 mesh using a pulverizer, ≪ / RTI >
상기에서 제조한 곡물류, 종실류 및 감초 추출물의 건조분말을 다음의 비율로 배합하여 제조하였다.The above-prepared cereal grains, seeds and dried powder of the licorice extract were blended in the following proportions.
곡물류 (현미 30 중량%, 율무 15 중량%, 보리 20 중량%),Cereals (30% by weight of brown rice, 15% by weight of yulmu, 20% by weight of barley)
종실류 (들깨 7 중량%, 검정콩 8 중량%, 검정깨 7 중량%),Seeds (7% by weight of perilla, 8% by weight of black beans, 7% by weight of black sesame seeds)
엉겅퀴 전초 추출물과 흰민들레 전초 추출물이 1:0.25 내지 1:4의 중량비로 혼합된 혼합물의 건조분말 (1 중량%),Dried powder (1% by weight) of a mixture of thistle outpost extract and white dandelion outpour extract mixed at a weight ratio of 1: 0.25 to 1: 4,
영지 (0.5 중량%), 및Manure (0.5% by weight), and
지황 (0.5 중량%)(0.5% by weight)
2-8. 탄산음료의 제조2-8. Manufacture of carbonated drinks
설탕 5~10%, 구연산 0.05 ~ 0.3 %, 카라멜 0.005 ~ 0.02 %, 비타민 C 0.1 ~ 1 %의 첨가물을 혼합하고, 여기에 79 ~ 94 %의 정제수를 섞어서 시럽을 만들었다. 상기에서 제조한 시럽을 85 ~ 98 ℃에서 20 ~ 180초 동안 살균하여 냉각수와 1 : 4의 비율로 혼합시킨 다음, 탄산가스를 0.5 ~ 0.82 % 주입하여 엉겅퀴 전초 추출물과 흰민들레 전초 추출물이 1:0.25 내지 1:4의 중량비로 혼합된 혼합물을 함유하는 탄산음료를 제조하였다.Syrup was prepared by mixing additives of 5 to 10% of sugar, 0.05 to 0.3% of citric acid, 0.005 to 0.02% of caramel and 0.1 to 1% of vitamin C and 79 to 94% of purified water. The syrup prepared above was sterilized at 85 to 98 ° C for 20 to 180 seconds, mixed with cooling water at a ratio of 1: 4, then carbon dioxide gas was injected at 0.5 to 0.82%, and the thistle outpost extract and white dandelion outpour extract were mixed at a ratio of 1: 0.25 to 1: 4 in the weight ratio.
2-9. 건강음료의 제조2-9. Manufacture of health drinks
액상과당 (0.5 %), 올리고당 (2 %), 설탕 (2 %), 식염 (0.5 %), 물 (75 %)과 같은 부재료에 엉겅퀴 전초 추출물과 흰민들레 전초 추출물이 1:0.25 내지 1:4의 중량비로 혼합된 혼합물을 균질하게 배합하여 순간 살균을 한 후 이를 유리병, 패트병 등 소포장 용기에 포장하여 건강음료를 제조하였다.The thistle outpost extract and the white dandelion outpost extract were added to the raw materials such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5%) and water (75% , The mixture was homogenized and sterilized instantaneously, and then packaged in a glass bottle, plastic bottle or other plastic container to prepare a health drink.
Claims (16)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160179611A KR101902932B1 (en) | 2016-12-27 | 2016-12-27 | A composition for preventing, improving or treating alcoholic gastritis of the extracts from the aerial parts except flower and root of Cirsium japonicum and Taraxacum coreanum |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160179611A KR101902932B1 (en) | 2016-12-27 | 2016-12-27 | A composition for preventing, improving or treating alcoholic gastritis of the extracts from the aerial parts except flower and root of Cirsium japonicum and Taraxacum coreanum |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180085079A KR20180085079A (en) | 2018-07-26 |
| KR101902932B1 true KR101902932B1 (en) | 2018-10-02 |
Family
ID=63047822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160179611A KR101902932B1 (en) | 2016-12-27 | 2016-12-27 | A composition for preventing, improving or treating alcoholic gastritis of the extracts from the aerial parts except flower and root of Cirsium japonicum and Taraxacum coreanum |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101902932B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210050033A (en) | 2019-10-25 | 2021-05-07 | 농업회사법인 주식회사 장수식품 | A composition for improving, preventing and treating of gastrointestinal disease |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102212264B1 (en) | 2019-02-26 | 2021-02-04 | (주)에코인베스트 | Feed additive for ameliorating fatty liver haemorrhagic syndrome comprising Taraxacum coreanum and Cirsium japonicum var. ussuriense |
| KR102302047B1 (en) * | 2019-12-11 | 2021-09-15 | 농업회사법인 주식회사 장수식품 | Composition for hepatoprotective and ameliorating hangover |
-
2016
- 2016-12-27 KR KR1020160179611A patent/KR101902932B1/en active IP Right Grant
Non-Patent Citations (2)
| Title |
|---|
| 약학회지. 2011. 제55권제2호, pp.160-167..* |
| 인터넷 기사. "민들레와 엉겅퀴, 약대 효과로 UP!". 메디컬 한의. (2013.01.13.).* |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210050033A (en) | 2019-10-25 | 2021-05-07 | 농업회사법인 주식회사 장수식품 | A composition for improving, preventing and treating of gastrointestinal disease |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180085079A (en) | 2018-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101522273B1 (en) | A composition comprising the extract of Curcuma aromatica SALISB for preventing and treating benign prostatic hyperplasia | |
| KR101902932B1 (en) | A composition for preventing, improving or treating alcoholic gastritis of the extracts from the aerial parts except flower and root of Cirsium japonicum and Taraxacum coreanum | |
| EP2535056A2 (en) | Composition for preventing or treating rotavirus infection containing licorice extract | |
| KR101018403B1 (en) | composition comprising the extract of soybean leaves for the prevention?delay or treatment of gout | |
| KR20140129492A (en) | Compositions Comprising a Leaf Extract of Cudrania tricuspidata for the Prevention and Treatment of Arthritis disease | |
| US20240115644A1 (en) | Composition for preventing, improving or treating gastritis or peptic ulcer comprising extract of cinnamomum cassia, fraction of said extract, isolate of said fraction or compounds isolated therefrom | |
| KR101070476B1 (en) | Composition containing extract of black onion for prevention and treatment of Gout or Hyperuricemia | |
| KR102414431B1 (en) | A composition for improving, preventing and treating of diabetes mellitus | |
| KR20070097868A (en) | Composition comprising an allium cepa l. skin extract for preventing and treating diabetes mellitus | |
| KR101282356B1 (en) | Composition comprising Acanthopanacis Cortex butanol fraction for preventing or treating gastrointestinal disease | |
| KR102019974B1 (en) | A composition for preventing, improving or treating alcoholic gastro-intestinal disease comprising the extracts from licorice and dandelion | |
| KR101001159B1 (en) | Composition for preventing or improving the diabete containing eriobotrya japonica extract | |
| KR20160121886A (en) | Composition that comprising Hericium erinaceus and Brassica oleraceavar capitata extract for enhancing gastrointestinal health which includes preventation or treatment heartburn, gastritis, gastric ulcer, gastric bleeding, injury of gastric mucosa and hyper secretion of gastric acid | |
| KR100888068B1 (en) | Compositions for suppressing obesity | |
| KR101605305B1 (en) | Composition comprising broussonetia kazinoki extract for preventing and treating diabetic complication | |
| KR20140026737A (en) | A composition comprising the powder of fermented curcuma longa l. for protecting alcoholic liver damage | |
| KR20150031373A (en) | Phamaceutical and food composition for preventing or treating obesity comprising extract of leaf from Hoppophea rhamnoids as effective component | |
| KR101565909B1 (en) | Composition for prevention and treatment of hepatic ischemia-reperfusion injury comprising extracts of Acanthopanax sp. | |
| KR102302047B1 (en) | Composition for hepatoprotective and ameliorating hangover | |
| KR102233672B1 (en) | A composition for improving, preventing and treating of diabetes mellitus comprising Milk thistle and Helianthus tuberosus | |
| KR102003354B1 (en) | Composition comprising Spike mulberry mistletoe extract for treating diabetes | |
| KR100539457B1 (en) | Composition For Preventing And Treating Hyperlipidemia, Arteriosclerosis And Fatty Liver Comprising The Extract Of Sophorae Fructus | |
| KR101705760B1 (en) | Composition for composition for prevention or treatment of rotavirus infection comprising ecklonia cava | |
| KR101659889B1 (en) | Composition comprising glycoprotein isolated from porphyra yezoensis for preventing or treating of viral liver damage | |
| KR20150031372A (en) | Phamaceutical and food composition for preventing or treating diabetes comprising extract of fruit from Hoppophea rhamnoids as effective component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant |